GSK Abreva Performance Claims Affirmed By NAD, Leave Novartis Sore
This article was originally published in The Tan Sheet
Executive Summary
Advertising claims that GlaxoSmithKline's cold-sore treatment Abreva "speeds healing like a prescription without one" are supported, the National Advertising Division of the Council of Better Business Bureaus concludes after a recent inquiry